- Case report
- Open Access
- Open Peer Review
Unsuspected pulmonary alveolar proteinosis in a patient with acquired immunodeficiency syndrome: a case report
© Tejwani et al; licensee BioMed Central Ltd. 2011
- Received: 20 February 2010
- Accepted: 1 February 2011
- Published: 1 February 2011
Diffuse lung infiltrates are a common finding in patients with acquired immunodeficiency syndrome and causes range from infectious processes to malignancies or interstitial lung diseases. Pulmonary alveolar proteinosis is a rare pulmonary disorder rarely reported in patients infected with human immunodeficiency virus. Secondary pulmonary alveolar proteinosis is associated with conditions involving functional impairment or reduced numbers of alveolar macrophages. It can be caused by hematologic malignancies, inhalation of toxic dust, fumes or gases, infectious or pharmacologic immunosuppression, or lysinuric protein intolerance.
A 42-year-old African American man infected with human immunodeficiency virus was admitted with chronic respiratory symptoms and diffuse pulmonary infiltrates. Chest computed tomography revealed bilateral spontaneous pneumothoraces, for which he required bilateral chest tubes. Initial laboratory investigations did not reveal any contributory conditions. Histological examination of a lung biopsy taken during video-assisted thoracoscopy showed pulmonary alveolar proteinosis concurrent with cytomegalovirus pneumonitis. After ganciclovir treatment, our patient showed radiologic and clinical improvement.
The differential diagnosis for patients with immunosuppression and lung infiltrates requires extensive investigations. As pulmonary alveolar proteinosis is rare, the diagnosis can be easily missed. Our case highlights the importance of invasive investigations and histology in the management of patients infected with human immunodeficiency virus and pulmonary disease who do not respond to empiric therapy.
- Human Immunodeficiency Virus
- Human Immunodeficiency Virus Infection
- Interstitial Lung Disease
- Pulmonary Alveolar Proteinosis
- Noninvasive Positive Pressure Ventilation
Pulmonary alveolar proteinosis (PAP) was first described in 1958 by Rosen et al.. It is a rare pulmonary disorder characterized by an abnormal accumulation of surfactant-derived material in the alveoli, leading to disease that ranges from mild symptoms with complete spontaneous resolution to progressive disease with ensuing respiratory failure [1, 2].
Associated infections have been reported in 5 to 20% of PAP cases. This wide range may be due to reporting bias or difficulties detecting infectious processes . The infectious agents include Nocardia asteroides, Mycobacterium tuberculosis, Mycobacterium avium-intracellulare, Pneumocystis jirovecii (formerly carinii) and cytomegalovirus (CMV). Most of these infectious agents have been reported in immunocompromised patients uninfected with human immunodeficiency virus (HIV); however, PAP is a rare finding in patients with HIV .
We present a unusual case of a patient with HIV infection admitted with chronic respiratory symptoms, diffuse pulmonary infiltrates and bilateral spontaneous pneumothoraces, who was found to have PAP concurrent with Cytomegalovirus pneumonitis. Our patient was a 42-year-old African-American man, who was admitted with fever, productive cough with whitish sputum, fatigue, and weight loss of 6.8 kg in the previous month. He reported no visual abnormalities, and denied traveling or relevant any medical or surgical history.
Our patient performed maintenance work, and smoked 20 packs of cigarettes per year, but denied alcohol or substance use. He had undergone testing for tuberculosis (purified protein derivative) in the previous year, which was negative.
Because of progressive dyspnea, our patient was transferred to the intensive care unit 24 hours after admission, where he underwent bilateral chest tube insertion. The initial differential diagnosis was community-acquired pneumonia or an opportunistic infection, typically Pneumocystis in a patient infected with HIV. Pneumothoraces and elevated LDH supported the diagnosis of Pneumocystis pneumonia (PCP), therefore antibiotics (ceftriaxone, azithromycin, trimethoprim-sulfamethoxazole) and corticosteroids were initiated. Sputum studies for PCP, acid-fast bacilli (AFB) and influenza were negative, as were blood and urine cultures. Our patient refused fiberoptic bronchoscopy.
Our patient's condition continued to deteriorate despite treatment. On the third day after admission, he required noninvasive positive pressure ventilation (fraction of inspired oxygen was 50%) to maintain O2 saturation at 92%. Because of a persistent air leak, two chest tubes were required in each lung, and on day six after admission, our patient underwent bilateral sequential video-assisted thoracoscopic surgery and lung biopsy. Histological examination of the biopsy revealed foamy macrophages, and PAS-positive, diastase-resistant and mucicarmine-negative material. Pneumocystis organisms were not detected by direct immunofluorescence with monoclonal antibodies. Histopathology revealed CMV inclusion bodies and proteinaceous material filling the alveoli.
Epidemiological data regarding the incidence and prevalence of PAP have been gathered from small case series and single case reports. The incidence of PAP is reported to be 0.36 to 0.49 cases per million in the population, with a prevalence of 3.70 to 6.2 cases per million. PAP occurs in all age groups, but is most common in men (male:female ratio 3:1) and among people aged 20 to 50 years. PAP is three times as common in smokers than in non-smokers, and in North America, 72% of patients with PAP are smokers [2, 4].
There are three clinically distinct forms of PAP: congenital (2% of cases), acquired (also referred as primary or idiopathic, 90%), and secondary (5 to10%) .Congenital PAP is a heterogeneous collection of disorders caused by homozygous mutation of the genes encoding surfactant proteins (SP)-B and SP-C and the ABCA3 (ATP-binding cassette, sub-family A, member 3) transporter, or by the absence of the granulocyte macrophage colony-stimulating factor (GM-CSF) receptor [3, 5]. Primary PAP is regarded as an autoimmune condition. It is characterized by excess surfactant caused by GM-CSF-neutralizing antibodies, receptor deficiency or gene deficiency/mutation, which leads to decreased macrophage stimulation. As a result, the immature alveolar macrophages are incapable of proper surfactant clearance [4–6]. Secondary PAP is uncommon, and develops in association with conditions involving functional impairment or reduced numbers of alveolar macrophages. It is caused by hematologic malignancies, inhalation of toxic dust, fumes or gases, infectious or pharmacologic immunosuppression, and lysinuric protein intolerance.
Patients infected with HIV have altered immunity and are susceptible to opportunistic lung infections. The subsequent breakdown of the alveolar lining, overproduction of substances normally secreted into the alveoli, impairment of alveolar clearance, and the transudation of plasma constituents into the alveoli may contribute to the pathogenesis of PAP . Despite these risk factors, few reports exist of PAP in patients infected with HIV, and those cases of PAP that have been reported have been primarily associated with P. jirovecii, mycobacteria. or rarely, CMV infections [7–10].
The clinical presentation of PAP varies from asymptomatic (31% of acquired cases) to a more chronic presentation with dyspnea (39%), dyspnea and cough (11%), or cough only (10%). Cough is usually nonproductive, but is sometimes accompanied by sputum described as 'white and gummy' or 'chunky'. Fever and weight loss can also occur.
The physical examination is typically nonspecific: crackles, clubbing and cyanosis all have been reported, but rarely . The radiographic findings are nonspecific, with chest radiography typically showing bilateral central and symmetric lung opacities with relative sparing of the apices and costophrenic angles, and less commonly, multifocal asymmetric opacities. Extensive diffuse consolidations have also been reported, suggesting interstitial pulmonary edema. Lymphadenopathy is rarely present. Chest CT findings are nonspecific and show smooth thickening of septal lines superimposed on areas of GGO, known as 'crazy paving'. A high-resolution CT study reported that secondary PAP was significantly more diffuse than autoimmune PAP. Pneumothoraces associated with PAP have been rarely reported, usually in association with PCP. In addition, a report suggests that emphysematous bullae in patients with PAP could lead to pneumothoraces [12–14].
Abnormal nonspecific laboratory findings in PAP include increased levels of serum LDH and other protein products of pulmonary epithelial cells such as carcinoembryonic antigen, cytokeratin 19, KL-6 mucin, SP-A, SP-B and SP-D . GM-CSF auto-antibodies are elevated in primary PAP, but normal in secondary and congenital PAP [2, 4]. Pulmonary function test usually reveals restrictive lung disease, decreased carbon monoxide diffusing capacity, increased alveolar-arterial partial oxygen pressure (PO2) gradient, hypoxemia and elevated shunt fraction.
The gold standard for PAP diagnosis is open lung biopsy, but fiberoptic bronchoscopy can diagnose up to 75% of PAP cases. Bronchoalveolar lavage and transbronchial biopsy are usually performed to exclude infection. The classic findings include a 'milky' fluid containing large amounts of granular acellular eosinophilic proteinaceous material, with morphologically abnormal 'foamy' macrophages engorged with diastase-resistant PAS-positive intracellular inclusions. Mucicarmine and PCP stains are negative, as in our case. When electron microscopy is available, the presence of concentrically laminated phospholipid structures called lamellar bodies can confirm the diagnosis [6, 11, 15]. Lung lavage fluid samples generally do not contain microbes, and it is now known that most cases of encountered infection are a secondary event rather than the initiating process .
Treatment of PAP depends on the physiologic impairment, rate of progression or remission and the underlying pathology. Supportive treatment and occasional lung transplantation are used for congenital PAP. Secondary PAP is managed with conservative therapy and treatment of the associated condition. In primary PAP, the standard of care is whole-lung lavage performed under general anesthesia. GM-CSF replacement is still experimental. The appropriateness of whole-lung lavage for secondary PAP with severe respiratory impairment is unclear at the present time [2, 3, 11].
In conclusion, the differential diagnosis of diffuse lung infiltrates in patients with acquired immunodeficiency syndrome requires extensive investigation, as causes range from infectious processes to malignancies or interstitial lung diseases. Pneumothoraces in patients with HIV infection are usually attributed to PCP infection or emphysema caused by tobacco use or by the HIV infection itself. PAP is rare in these patients, thus it can easily be misdiagnosed. Clinicians caring for patients infected with HIV must consider PAP, either alone or in combination with CMV or other opportunistic infection, during the differential diagnosis. Tissue diagnosis is important, as is careful histological examination of bronchoscopic lavage fluid and biopsies. A surgical lung biopsy should be considered in cases of infiltrates of unclear etiology or progressive clinical deterioration despite treatment.
Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Rosen SH, Castleman B, Liebow AA: Pulmonary alveolar proteinosis. N Engl J Med. 1958, 258: 1123-1142. 10.1056/NEJM195806052582301.View ArticlePubMedGoogle Scholar
- Seymour JF, Presneill JJ: Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002, 166: 215-235. 10.1164/rccm.2109105.View ArticlePubMedGoogle Scholar
- Goldstein LS, Kavuru MS, Curtis-McCarthy P, Christie HA, Farver C, Stoller JK: Pulmonary alveolar proteinosis. Clinical features and outcomes. Chest. 1998, 114: 1357-1362. 10.1378/chest.114.5.1357.View ArticlePubMedGoogle Scholar
- Greenhill SR, Kotton DN: Pulmonary Alveolar Proteinosis. A bench-to-bedside story of granulocyte-macrophage colony-stimulating factor dysfunction. Chest. 2009, 136: 571-577. 10.1378/chest.08-2943.View ArticlePubMedGoogle Scholar
- Trapnell BC, Whitsett JA, Nakata K: Pulmonary alveolar proteinosis. N Engl J Med. 2003, 349: 2527-39. 10.1056/NEJMra023226.View ArticlePubMedGoogle Scholar
- Juvet SC, Hwang D, Waddell TK, Downey GP: Rare lung diseases II: Pulmonary alveolar proteinosis. Can Respir J. 2008, 15: 203-210.View ArticlePubMedPubMed CentralGoogle Scholar
- Israel R, Magnussen CR: Are AIDS patients at risk for pulmonary alveolar proteinosis?. Chest. 1989, 96: 641-642. 10.1378/chest.96.3.641.View ArticlePubMedGoogle Scholar
- Jean R, Nezelof C, Bonnet H, Meylan F, Imbert MC: Proteinosis and pulmonary cytomegalic inclusions associated with thymic alymphoplasia. Arch Fr Pediatr. 1968, 25: 1009-1021.PubMedGoogle Scholar
- Ranchod M, Bissell M: Alveolar proteinosis and cytomegalovirus infection. Pathol Lab Med. 1979, 103: 139-42.Google Scholar
- Pilavaki M, Smias C, Palladas P: Pulmonary alveolar proteinosis in an immunosuppressed patient with cytomegalovirus infection. Archivos de bronconeumologia. 2009, 5: 204-205. 10.1016/j.arbres.2008.05.006.Google Scholar
- Huizar I, Kavuru MS: Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management. Opinion in Pulmonary Medicine. 2009, 15: 491-498. 10.1097/MCP.0b013e32832ea51c.View ArticleGoogle Scholar
- Frazier AA, Franks TJ, Cooke EO, Mohammed TL, Pugatch RD, Galvin JR: From the archives of the AFIP: pulmonary alveolar proteinosis. RadioGraphics. 2008, 28: 883-899. 10.1148/rg.283075219.View ArticlePubMedGoogle Scholar
- Lee KN, Levin DL, Webb WR, Chen D, Stortoml , Golden JA: Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic and functional correlations. Chest. 1997, 111: 989-995. 10.1378/chest.111.4.989.View ArticlePubMedGoogle Scholar
- Ishii H, Trapnell BC, Tazawa R, Inoue Y, Akira M, Kogure Y, Tomii K, Takada T, Hojo M, Ichiwata T, Goto H, Nakata K, Japanese Center of the Rare Lung Disease Consortium: Comparative study of high-resolution ct findings between autoimmune and secondary pulmonary alveolar proteinosis. Chest. 2009, 136: 1348-1355. 10.1378/chest.09-0097.View ArticlePubMedGoogle Scholar
- Wang BM, Stern EJ, Schmidt RA, Pierson DJ: Diagnosing pulmonary alveolar proteinosis. A review and an update. Chest. 1997, 111: 460-466. 10.1378/chest.111.2.460.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.